All News
Alive in 2025 (1.10.2025)
Dr. Jack Cush brings in the new year with a review of the latest from RheumNow.com
Read Article
GLP-1 Agonists Alleviate Knee Osteoarthritis
In October, the NEJM published a randomized clinical trial demonstrating the efficacy of glucagon-like peptide-1 receptor agonists (GLP-1ra) in patients with obesity and knee osteoarthritis.
Read Article
Does Colchicine Lower Gout Mortality Risk?
Data from a large UK database finds that gout patients starting urate-lowering therapy (ULT) will benefit from added colchicine prophylaxis by having fewer cardiovascular events.
Read Article
EULAR: Considerations when Transitioning from Pediatric to Adult Rheumatologic Care
EULAR has established guidance on best practices for delivering patient education in physical activity and self-management of pain during transitional care in rheumatology.
Anti-Zoster Drug Prevents Shingles in Lupus Patients on Anifrolumab
MedPage Today
The antiviral drug valaciclovir (Valtrex), given prophylactically, kept patients with systemic lupus erythematosus (SLE) under treatment with anifrolumab (Saphnelo) from having herpes zoster attacks, researchers said, offering a potential alternative to zoster vaccination.
Read Article
Network metanalysis of 9 RCTs, 3699 patients looked at small molecule Rx in #PsA. With ACR 50/70, PASI 75, & HAQ-DI @ wk 12-16, UPA was > ADA in PASI75 (RR 1.2); Deucravacitinib > Otezla at HAQ (RR −0.16) no OTHER SIGNIF differences observed https://t.co/T0eMkXrxQX https://t.co/FCkbuhi1ze
Dr. John Cush RheumNow ( View Tweet)
A Modifiable Vascular Risk in SLE
Atherosclerosis progression was more than 2x as common in younger people with SLE than in healthy controls in a prospective study from Greece.
https://t.co/zGTGin664D https://t.co/ZO9UlIPNIi
Dr. John Cush RheumNow ( View Tweet)
Online, lifestyle intervention program shown to have positive long-term effects in 264 patients w/ Inflam Arthritis, OA & FM , even after 2-yrs. Prg focused on nutrition, exercise, relaxation & sleep. Signif reductions in Wt, BMI, and PRO's (pain, Am stiff, fatigue)… https://t.co/vghObYPnvW https://t.co/ZSdFPWel57
Dr. John Cush RheumNow ( View Tweet)
Study of 1032 adults > 50 yrs on dialysis compared denosumab vs or oral bisphosphonates. 3 yr results showed compared with oral bisphosphonates, denosumab lowered the risk for fractures by 45% and increased the risk for MACE by 36% https://t.co/aogIFBrccy https://t.co/cnlxt5OEjj
Dr. John Cush RheumNow ( View Tweet)
Marketscan claims data study assessed fall risk in 57 086 older adult starting gabapentin vs duloxetine & found gabapentin was not associated with increase in falls. At 6-mos, gabapentin had lower risk of falls (HR 0.52; 0.43 to 0.64]. https://t.co/agrdzkxNdL https://t.co/Te981iDMZU
Dr. John Cush RheumNow ( View Tweet)
Prevalence of Autoimmune Diseases in the United States
An epidemiologic assessment of the prevalence of autoimmune diseases in the United States (US) finds that nearly 5% of the population has an autoimmune disorder, twice as many in women compared to men.… https://t.co/L5BusRvcFP https://t.co/JTw8CXf1Tq
Dr. John Cush RheumNow ( View Tweet)
Study of 1032 adults > 50 yrs on dialysis compared denosumab vs or oral bisphosphonates. 3 yr results showed compared with oral bisphosphonates, denosumab lowered the risk for fractures by 45% and increased the risk for MACE by 36% https://t.co/evaTc8Ag5Y https://t.co/wps14UddgP
Dr. John Cush RheumNow ( View Tweet)
Real world observations from 65 RA-ILD pts Rx w/ nintendinb (95% on DMARDs/Pred) in Italian GISEA registry. 12 mos retention rate = 77% & was effective ~80% in pts w/ > 6 months F/U. Side effects in 55% (mainly GI) & ~1/2 had to reduce dose. 23% D/C drug for AE.… https://t.co/aVcIYtoMK4 https://t.co/CBHxzBc9XQ
Dr. John Cush RheumNow ( View Tweet)
Spanish registry ARTESER, looked at GCA outcomes from 2013 to 2019. In 1200 GCA pts ~ 2 yrs F/U, The 5-Yr mortality 37.9/1000 pt/yrs; higher in males vs females (59 vs 29 p<0.001), but was same as gen population . Incr mortality w/ age & male sex. HA & Hgb were protective… https://t.co/idnuUL9Kog https://t.co/2MsOxuTtCd
Dr. John Cush RheumNow ( View Tweet)
Review of of nurse-led care (NLC) vs Rheum-led (RLC) vs Usual care in RA pts - 14 studies, 3369 pts. shows NLC proves highly effective in managing RA patients, surpassing usual care and equating to rheumatologist-led care in primary and secondary outcomes.… https://t.co/evpFTT9n22 https://t.co/n8ncKG9SFt
Dr. John Cush RheumNow ( View Tweet)
In #RA, Higher levels of ESR and CRP, but not DAS28, joint counts or global assessments, were significantly associated with the risk of incident ILD in RA. German biologics (RABBIT) registry study compared 139 RA-ILD vs vs 686 controls. https://t.co/Ul4HZ1hzS0 https://t.co/GLKL7U4ASt
Dr. John Cush RheumNow ( View Tweet)
Benefit of Achieving Target Serum Urate Levels in Gout with Chronic Kidney Disease
A cohort study of gout patients with CKD stage 3 found that lowering serum urate (SUA) level to less than 6 mg/dL, lowered the risk for severe or end-stage kidney disease progression.… https://t.co/NsGUGvb5L5 https://t.co/QPBWA4VqTo
Dr. John Cush RheumNow ( View Tweet)
12 mos study of RCT 179 gout pts starting allopurinol finds that betw mos 6-12, gout flares went down. 38% had no flares, 19% had 1 flare, & 43% had >1 flare in 2nd 6 mos. # flares equates to control and impact of gout on outcomes. https://t.co/TMwXZStbJU
Dr. John Cush RheumNow ( View Tweet)
nline, lifestyle intervention program shown to have positive long-term effects in 264 patients w/ Inflam Arthritis, OA & FM , even after 2-yrs. Prg focused on nutrition, exercise, relaxation & sleep. Signif reductions in Wt, BMI, and PRO's (pain, Am stiff, fatigue)… https://t.co/ImNzTZGLut https://t.co/rAn8llwnjP
Dr. John Cush RheumNow ( View Tweet)
Sedentary Behavior Increases the Risk of Gout
NHANES national survey study shows that sedentary behavior is an independent risk factor for gout, especially in those without hyperuricemia.
https://t.co/LDhK3iDnrS https://t.co/z6I6tRw9Fr
Dr. John Cush RheumNow ( View Tweet)
